Phase 3 Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have active psoriatic arthritis (PsA) that has not been fully controlled despite having tried at least one of the following: a non-biologic DMARD medication, apremilast, or one biologic medication
- People who have had a confirmed diagnosis of PsA for at least 3 months before the first study treatment, and whose condition meets a recognised set of classification criteria for PsA (called CASPAR criteria) at the screening visit
- People who have active PsA at both the screening and baseline visits, meaning at least 3 swollen joints and at least 3 tender joints, plus a blood marker of inflammation (CRP) at or above a certain level on a central lab test
- People whose PsA falls into at least one of these subtypes: involvement of the small joints at the tips of the fingers or toes, arthritis affecting many joints without rheumatoid nodules, a severe destructive form of arthritis (arthritis mutilans), arthritis affecting joints unevenly on the body, or spinal inflammation combined with joint involvement
- People who have active plaque psoriasis with at least one skin plaque of 2 cm or more in size, or nail changes consistent with psoriasis
- Female participants of childbearing potential must have a negative blood pregnancy test at screening and a negative urine pregnancy test before the first study treatment is given
Who may not be able to join:
- People who have a history of, or currently have signs or symptoms of, serious or uncontrolled problems affecting the kidneys, liver, heart, blood vessels, lungs, gut, hormonal system, nervous system, blood, joints (other than PsA), mental health, urinary or reproductive system, or metabolism
- People who currently have cancer, or who have had cancer at any point in the 5 years before the screening visit
- People who have a known allergy, sensitivity, or intolerance to the study drug (icotrokinra) or any of its ingredients
- People who have other inflammatory conditions that could make it difficult to assess how well the study treatment is working — for example, rheumatoid arthritis, lupus, or Lyme disease
- People who have fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, could interfere with the ability to accurately measure the trial's effectiveness
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Participants who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.